CALGB 100801 (Alliance): A phase II multi-center study of the addition of azacitidine (AZA) following allogeneic transplantation using a targeted busulfan based conditioning regimen for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML) Vij, Ravi , Hars, Vera , Blum, William , Shore, Tsiporah ... - EBMT - Bone Marrow Transplantation - 2015 Abstract - Primary - Primary - Transplant - CALGB-100801